Cantor Fitzgerald Lowers Earnings Estimates for Scholar Rock

Scholar Rock Holding Corporation (NASDAQ:SRRK) – Investment analysts at Cantor Fitzgerald dropped their FY2025 earnings estimates for Scholar Rock in a report released on Monday, November 17th. Cantor Fitzgerald analyst E. Schmidt now forecasts that the company will post earnings of ($3.51) per share for the year, down from their prior forecast of ($3.41). The consensus estimate for Scholar Rock’s current full-year earnings is ($2.42) per share. Cantor Fitzgerald also issued estimates for Scholar Rock’s FY2026 earnings at ($3.49) EPS.

Other equities research analysts also recently issued research reports about the company. Jefferies Financial Group initiated coverage on Scholar Rock in a research report on Thursday, August 21st. They issued a “buy” rating and a $50.00 price objective for the company. JPMorgan Chase & Co. increased their target price on Scholar Rock from $46.00 to $47.00 and gave the stock an “overweight” rating in a research report on Tuesday. Leerink Partnrs raised Scholar Rock to a “strong-buy” rating in a research note on Monday, September 15th. Barclays upped their price objective on shares of Scholar Rock from $44.00 to $45.00 and gave the company an “overweight” rating in a research note on Monday. Finally, BMO Capital Markets reiterated an “outperform” rating and set a $50.00 price objective on shares of Scholar Rock in a report on Friday. Three analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Scholar Rock presently has a consensus rating of “Buy” and a consensus target price of $48.33.

Scholar Rock Trading Up 9.2%

Shares of SRRK opened at $39.81 on Wednesday. Scholar Rock has a fifty-two week low of $22.71 and a fifty-two week high of $46.98. The company has a market capitalization of $3.83 billion, a PE ratio of -13.68 and a beta of 0.79. The stock has a fifty day moving average of $32.71 and a two-hundred day moving average of $33.47. The company has a debt-to-equity ratio of 0.21, a quick ratio of 6.33 and a current ratio of 6.33.

Scholar Rock (NASDAQ:SRRK) last announced its quarterly earnings data on Friday, November 14th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.88) by ($0.02). During the same quarter last year, the firm earned ($0.66) EPS.

Hedge Funds Weigh In On Scholar Rock

Hedge funds and other institutional investors have recently made changes to their positions in the business. Wellington Management Group LLP boosted its position in shares of Scholar Rock by 124.5% in the third quarter. Wellington Management Group LLP now owns 4,545,887 shares of the company’s stock worth $169,289,000 after buying an additional 2,521,022 shares during the period. Holocene Advisors LP purchased a new stake in shares of Scholar Rock during the 3rd quarter valued at about $91,670,000. Vestal Point Capital LP acquired a new position in Scholar Rock during the 1st quarter worth approximately $41,795,000. Norges Bank purchased a new position in Scholar Rock in the 2nd quarter worth approximately $41,628,000. Finally, RA Capital Management L.P. boosted its holdings in Scholar Rock by 6,351.3% in the 1st quarter. RA Capital Management L.P. now owns 1,136,453 shares of the company’s stock worth $36,537,000 after acquiring an additional 1,118,837 shares during the period. Institutional investors and hedge funds own 91.08% of the company’s stock.

Insider Activity

In other Scholar Rock news, insider Mo Qatanani sold 3,353 shares of Scholar Rock stock in a transaction that occurred on Monday, September 22nd. The shares were sold at an average price of $30.67, for a total transaction of $102,836.51. Following the transaction, the insider directly owned 108,964 shares of the company’s stock, valued at $3,341,925.88. The trade was a 2.99% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Srinivas Akkaraju acquired 387,414 shares of the firm’s stock in a transaction on Friday, October 3rd. The shares were acquired at an average price of $37.27 per share, with a total value of $14,438,919.78. Following the completion of the purchase, the director owned 387,414 shares of the company’s stock, valued at $14,438,919.78. This trade represents a ∞ increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have sold 7,537 shares of company stock valued at $242,088 in the last three months. Corporate insiders own 13.30% of the company’s stock.

Scholar Rock Company Profile

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.